Hyderabad: Dr. Reddy’s on Thursday announced the launch of Penicillamine capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine® (penicillamine) capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA), in the United States of America.
The Cuprimine brand and generic market had sales worth approximately $80 million in the USA for the most recent 12 months, ending in June, 2020, according to IQVIA Health.
However the company has also issued a warning against the drug, The manufacturers said, ” Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity”.
Dr. Reddy’s Penicillamine capsules USP (250 mg) is available in a bottle count sizes of 100.
Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.